ArticleScientific reports2025
Multi-omics and machine learning refine HCC molecular subtypes and prognosis based on liquid-liquid phase separation related genes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Accumulating evidence has demonstrated that biological processes associated with liquid-liquid phase separation (LLPS) play a critical role in cancer development. However, the effect of LLPS on hepatocellular carcinoma (HCC) remains largely unknown. In this study, we integrated consensus clustering with an ensemble machine learning framework to establish robust LLPS-related molecular subtypes and a consensus machine learning-driven LLPS-related signature (CMLLS) for HCC. The consensus clustering robustly identified three fundamental LLPS-driven subtypes (LS1-LS3), and the subsequent machine learning integration, which encompassed 101 algorithm combinations, objectively identified the most generalizable prognostic signature from multiple candidate genes. Our analysis revealed that LS3 exhibits the worst prognosis, significant upregulation of cell cycle and epithelial-mesenchymal transition (EMT)-related pathways, and enhanced immune resistance. Conversely, LS2 displays the best prognosis, enrichment in metabolism-related pathways, and increased sensitivity to immunotherapy. The CMLLS demonstrated robust predictive performance in prognostic stratification and effectively distinguished patients who would benefit from immunotherapy. This study provides novel insights into HCC heterogeneity at the LLPS level and offers a powerful tool for individualized treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.